AID utilises facilities housed across the Centre, including at the Institute for Molecular Bioscience and the Australian Institute for Bioengineering and Nanotechnology.
AID researchers possess a strong translational record in the field of vaccinology, notably in the development of new vaccines, the development of the needle-less nanopatch vaccine delivery system and the formulation of novel adjuvants.
AID researchers have expertise in:
- Vaccines and adjuvants
- Vaccine delivery technologies
- Nanocoatings
- Post-vaccine surveillance and correlates of protection
- Clinical practices for preventing hospital-acquired infection
Impact:
- UQ molecular clamp vaccine technology platform commercialised through spin-off Vicebio, acquired for US$1.15bn by Sanofi
- Key expertise and research for $280M Translational Sciences Hub Sanofi/UQ/Griffith/QLD Gov
- Key expertise and capabilities for QLD-Emory Vaccine Centre (QEVC)
- mRNA vaccine capabilities for partnerships with major pharma
- Field surveillance and decision support tools for governments
AID consolidates assay development, screening, compound libraries, chemoinformatics, modelling, synthetic and medicinal chemistry capacity into one location for application against infectious disease agents. Our capacity can be used to move into pre-clinical and clinical studies at the QIMR Berghofer Medical Research Institute/Herston site.
A pledge to AID goes directly into the research of issues that impact the lives of many people and their families.